MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Phase 1 Completed 27 enrolled Morphotek Children's Oncology Group · collab National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies the side effects and best dose of MORAb-004 in treating young patients with recurrent or refractory solid tumors or lymphoma. Monoclonal antibodies, such as MORAb-004, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them

Timeline

Start: 2013-11
Primary completion: 2015-05
Completion: 2015-05

Publications

Norris RE, Fox E, Reid JM, Ralya A, Liu XW, Minard C, Weigel BJ. Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer. 2018 May;65(5):e26944. doi: 10.1002/pbc.26944. Epub 2018 Jan 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ontuxizumab	Monoclonal antibody	4 mg/kg	Intravenous
Subject	Ontuxizumab	Monoclonal antibody	8 mg/kg	Intravenous
Subject	Ontuxizumab	Monoclonal antibody	12 mg/kg	Intravenous

MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Summary

Timeline

Publications

Drugs

Indications